AI Chases 150-Year Lifespan

Scientist in hazmat suit using a transparent digital tablet in a lab — Photo: Iokanan VFX Studios / Shutterstock

Scientists now have a number to argue over: 150 years old, the age researchers say may mark the outer limit of human life.

Story Snapshot

A study of over 540,000 volunteers estimates humans lose the ability to bounce back from illness between ages 120 and 150.
An AI-discovered drug called rentosertib reversed signs of biological aging in a small human trial.
The Food and Drug Administration (FDA) still treats aging as a natural process, not a disease, blocking a direct approval path.
Billions of investment dollars are pouring into longevity biotech even though no anti-aging drug has ever been proven to extend human life in a clinical trial.

A Scientific Ceiling Near 150 Years

Researchers at Gero, a Singapore-based biotech firm, and Roswell Park Comprehensive Cancer Center in Buffalo studied health data from more than 540,000 people, plus a second group of over 4,500. They tracked how fast people recover from physical stress using fitness trackers and blood tests. Their conclusion: somewhere between age 120 and 150, the human body loses its last bit of resilience, making survival past that point essentially impossible.

That number has become a rallying point for a growing industry betting that artificial intelligence can push the boundaries of healthy aging, even if it can’t rewrite the biological ceiling itself. The pitch is simple. Let machine learning models comb through massive piles of genetic, protein, and cellular data to find drug targets faster than human researchers ever could.

An AI-Discovered Drug Already in Human Trials

Insilico Medicine, a biotech company, says its AI-discovered drug rentosertib reversed markers of biological age in a Phase IIa clinical trial involving 42 participants. Researchers measured results using six separate aging clocks built from blood protein data, and reported that lung function improved as the dose increased. The company published its findings in Nature Biotechnology, giving the longevity field one of its first human trial results tied directly to an AI-designed compound.

That result matters because so few AI-discovered drugs have made it this far. A 2024 review of 20 AI-driven drug programs found the technology cut screening and lead-optimization time by 30 to 50 percent compared to older methods. Speed, though, is not the same as proof. Getting a drug through years of human testing still takes patience science cannot shortcut.

The Regulatory Wall Standing in the Way

No company is close to winning Food and Drug Administration approval for a drug that treats aging itself, because the agency does not recognize aging as a disease. The agency approves treatments for specific conditions like diabetes or heart failure, not for growing old. One pharmaceutical executive put it bluntly: regulators will approve a drug for an age-related disease, but not an “anti-aging” pill by name.

That has not stopped the agency from investing in the groundwork. It has committed up to 144 million dollars over five years to seven research teams building tools to measure healthspan, including a Stanford Medicine team developing a scoring system to test whether early intervention can delay age-related decline. The money signals official interest, even without a clear approval pathway yet in place.

Billions Betting on a Field Still in Its Infancy

Momentum is building financially, too. Fidelity reports the FDA approved 50 new drugs in 2024 and 46 in 2025, including what researchers are calling the first class of longevity therapeutics, while big pharmaceutical companies spent more than 65 billion dollars acquiring biotech firms through October 2025.

History offers a reason for caution, not panic. No gerotherapeutic drug has ever been shown to extend human lifespan in a high-quality clinical trial. Earlier hopefuls like resveratrol delayed aging in animal studies but never delivered the same results in people. Roughly 90 percent of drug candidates that enter clinical trials still fail to win approval, AI involvement or not. That track record does not kill the longevity dream. It just means the next breakthrough still has to survive the same brutal testing every drug before it has faced, 150-year ceiling or not.